Cooperative Agreement U01CA301426
Award Date
7/25/25
Completion Date
5/31/30
Dollars Obligated
$641K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Cooperative Agreement
Place of Performance
Stanford, CA 94305, USA
Similar Awards
This $113,147 federal Project Grant award was provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) to The Leland Stanford Junior University. The grant will fund a 5-year career development program for Dr. Chris McGinnis to prepare him for an independent research career in cancer immunology, focusing on studying tumor-immune interactions during metastasis. The key objectives are to: 1) Use longitudinal single-cell RNA sequencing to uncover novel mechanisms of...
This $509,448 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) supports research by The Leland Stanford Junior University to investigate antigen-presenting cells in lymph nodes and their role in modulating metastatic tumor progression. The key objectives are to: 1) identify the specific antigen-presenting cell populations responsible for promoting tumor-specific regulatory T cell development, and 2) assess therapeutic strategies to reprogram...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $667,118.00 to The Regents of the University of California, San Francisco to conduct research aimed at "Identifying and Disabling New Pathways for Macromolecular Recycling in Pancreatic Cancer". The 5-year project, beginning on April 1, 2025, will systematically analyze pancreatic cancer cell lysosomes to identify key proteins that enable pro-survival catabolic...
This federal Cooperative Agreement award, funded by the National Cancer Institute under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353), aims to create a comprehensive 3D atlas depicting the progression of pancreatic cancer precursor lesions to invasive pancreatic ductal adenocarcinoma (PDAC) in individuals with genetic defects in DNA repair genes (BRCA1, BRCA2, PALB2). The $1,035,138 award, with a period of performance from Sep 1, 2024 to Aug 31, 2029, will support...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $639,882 to the University of North Carolina at Chapel Hill to conduct research aimed at elucidating the molecular mechanisms underlying metastasis organ tropism in breast cancer. The project will utilize a comprehensive dataset of human primary and metastatic tumor samples, as well as genetically engineered mouse models, to identify the molecular determinants driving lung and...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) is supporting research at The Leland Stanford Junior University (Stanford University) to investigate tumor microenvironmental biomarkers of breast cancer invasion. The $648,428 award aims to: 1) identify features of the ductal carcinoma in situ (DCIS) cells and collagen stroma that are spatially correlated with invasion, 2) determine the driver role of macrophage and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $654,197 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on pancreatic cancer patient-derived xenograft (PDX) tumor models. The research aims to: Define the molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) that respond to standard-of-care chemotherapies like FOLFIRINOX and gemcitabine + Abraxane. Elucidate how...
This $1,130,538 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a targeted therapeutic strategy against metastatic pancreatic ductal adenocarcinoma (PDAC) using a newly developed anti-Tn (AREMAB6) monoclonal antibody. The key objectives are to: 1) determine how the Tn antigen enhances PDAC progression and identify Tn-expressing glycoproteins; 2) validate the role of natural killer cells in AREMAB6-mediated...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $170,655.00 to The Leland Stanford Junior University to develop a new molecular method for mapping protein trafficking between glioblastoma (GBM) cells and other brain cell populations in an in vivo setting. The goal is to better understand the intercellular crosstalk that promotes chemoresistance, invasion, and angiogenesis in GBM, which has an average survival of 15-18...
This Project Grant award, with a total funding of $138,742, was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The primary awardee, The Johns Hopkins University, will utilize single-cell RNA sequencing data to develop statistical methods for identifying cellular interactions that are altered by combination immunotherapy treatments in pancreatic ductal adenocarcinoma (PDAC). Additionally, the award will support experiments...